3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
3
Recruiting
3
Not yet recruiting
3
Unknown
2
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
84
Ovarian Neoplasms
35
Breast Neoplasms
32
Lung Neoplasms
28
Uterine Cervical Neoplasms
18
Triple Negative Breast Neoplasms
15
Fallopian Tube Neoplasms
15
Carcinoma, Ovarian Epithelial
15
Small Cell Lung Carcinoma
13
Squamous Cell Carcinoma of Head and Neck
10
Neuroblastoma
10
Esophageal Neoplasms
9
Esophageal Squamous Cell Carcinoma
8
Central Nervous System Neoplasms
8
Recurrence
7
Head and Neck Neoplasms
6
Endometrial Neoplasms
6
Retinoblastoma
5
Neoplasm Metastasis
5
Brain Neoplasms
5
Adenocarcinoma of Lung
5
Testicular Neoplasms
3
Oligodendroglioma
3
Neoplasms
3
Melanoma
3
Medulloblastoma
3
Lymphoma, Large B-Cell, Diffuse
3
Hodgkin Disease
3
Glioblastoma
3
Carcinoma, Squamous Cell
3
Interventions
Gefitinib
5
icotinib
4
Pemetrexed
4
Docetaxel
4
camrelizumab
3
apatinib
3
anlotinib
3
aflutinib
3
Erlotinib Hydrochloride
3
osimertinib
2
dacomitinib
2
Thalidomide
2
Radiosurgery
2
Drug Therapy
2
Carboplatin
2
Afatinib
2
trilaciclib
1
spartalizumab
1
pembrolizumab
1
nimotuzumab
1
famitinib
1
envafolimab
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
S 1 (combination)
1
Radiofrequency Ablation
1
Microphysiological Systems
1
Immune Checkpoint Inhibitors
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
NSCLC
×
Carboplatin
×
Clear all
NCT03799601
2019-01-10
ALTER-L013
Tongji Hospital
Phase 4
Unknown
45 enrolled
NCT03656393
2018-09-04
RCTACSCNSCLC
Shenzhen People's Hospital
Phase 3
Unknown
48 enrolled